ALIM - Alimera Sciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.145
+0.115 (+11.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.030
Open1.040
Bid1.040 x 3000
Ask1.200 x 2900
Day's Range1.030 - 1.160
52 Week Range0.740 - 1.650
Volume120,981
Avg. Volume166,085
Market Cap80.194M
Beta2.43
PE Ratio (TTM)N/A
EPS (TTM)-0.336
Earnings DateJul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.70
Trade prices are not sourced from all markets
  • Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018
    PR Newswireyesterday

    Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018

    ATLANTA , July 18, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release ...

  • Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting
    PR Newswire8 days ago

    Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

    ATLANTA , July 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that ...

  • InvestorPlace14 days ago

    Alimera Stock Grew 25 Percent and It Is Just Getting Warmed Up

    With that said, what drove Alimera stock higher last week? On May 31, Alimera announced that the Spanish Ministry of Health approved the pricing and reimbursement of ILUVIEN, a drug that treats patients suffering from vision issues related to chronic diabetic macular edema (DME). The full reimbursement in the region should drive revenue growth higher in the quarters ahead.

  • Benzinga20 days ago

    B. Riley FBR: 3 Reasons To Buy Alimera Sciences

    Nano-cap pharma company  Alimera Sciences Inc (NASDAQ: ALIM ) could nearly triple in value for three key reasons, according to B. Riley FBR.  The Analyst Analyst Andrew D'Silva initiated coverage of Alimera ...

  • When Will Alimera Sciences Inc (NASDAQ:ALIM) Turn A Profit?
    Simply Wall St.22 days ago

    When Will Alimera Sciences Inc (NASDAQ:ALIM) Turn A Profit?

    Alimera Sciences Inc’s (NASDAQ:ALIM): Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. With the latestRead More...

  • Alimera Sciences Appoints Mary T. Szela to its Board of Directors
    PR Newswire28 days ago

    Alimera Sciences Appoints Mary T. Szela to its Board of Directors

    ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors.  Ms. Szela is currently the Chief Executive Officer and President of Surefire Medical Inc., which develops infusion technologies for cancer care. Ms. Szela brings extensive medical management and leadership experience to Alimera's Board. Prior to joining Surefire Medical as its CEO and President, Ms. Szela served as CEO of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics.  Prior to Novelion, she was CEO of Melinta Therapeutics.  Ms. Szela held ascending management positions at Abbott Laboratories, including President of the company's $8 billion U.S. pharmaceutical business.  She developed global brands such as Humira® and served as Vice President for global strategic marketing and services.

  • The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability
    PR Newswirelast month

    The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

    ATLANTA, June 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom (UK) National Institute for Health and Care Excellence (NICE) will undertake a partial review and appraisal of Technology Assessment 301. Currently reimbursement of ILUVIEN in England and Wales is only available for patients who have had their natural lens replaced with an artificial one (termed "pseudophakic").

  • Alimera Sciences Terminates At-the-Market Offering Agreement
    PR Newswirelast month

    Alimera Sciences Terminates At-the-Market Offering Agreement

    ATLANTA, June 4, 2018 /PRNewswire/ -- Alimera Sciences (ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank to sell, at the company's request, up to $25 million in shares of its common stock in an "at-the-market" equity program. Alimera has not sold and will not sell any shares under this program. "We believe our financing with Solar Capital has sufficiently capitalized the company to advance ILUVIEN's continued growth and success toward profitability.

  • Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain
    PR Newswire2 months ago

    Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain

    ATLANTA, May 31, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Sciences Limited, received a positive resolution for the pricing and reimbursement approval for ILUVIEN® from the Spanish Ministry of Health on May 11, 2018. This means that in Spain, ILUVIEN should be fully reimbursed for use in line with the European label indication with a restriction to patients with an artificial lens implanted. This approval was sought and secured by Alimera's distributor partner in Spain, Brill Pharma (Brill).

  • PR Newswire2 months ago

    Alimera Sciences to Present at the 8th Annual LD Micro Invitational Conference

    ATLANTA , May 22, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that CEO Dan Myers ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ALIM earnings conference call or presentation 3-May-18 1:00pm GMT

    Q1 2018 Alimera Sciences Inc Earnings Call

  • ACCESSWIRE3 months ago

    Alimera Sciences Reports First Quarter 2018 Results

    Net Revenue in Q1 of 2018 increased 48% over Q1 of 2017 U.S. Net Revenue increased 59% in Q1 of 2018 over Q1 of 2017 International Revenue in Q1 of 2018 increased 27% over Q1 of 2017 End User Demand in ...

  • ACCESSWIRE3 months ago

    Alimera Sciences to Report First Quarter 2018 Results May 2, 2018

    ATLANTA, GA / ACCESSWIRE / April 24, 2018 / Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release ...

  • ACCESSWIRE3 months ago

    Alimera Sciences Announces Data from 19 Iluvien(R) Studies to be Presented at 2018 ARVO

    ATLANTA, GA / ACCESSWIRE / April 24, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ALIM earnings conference call or presentation 1-Mar-18 2:00pm GMT

    Q4 2017 Alimera Sciences Inc Earnings Call

  • ACCESSWIRE5 months ago

    Alimera Sciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 9:00 AM Eastern Time. ...

  • Associated Press5 months ago

    Alimera Sciences reports 4Q loss

    The Alpharetta, Georgia-based company said it had a loss of 10 cents per share. The eye drug developer posted revenue of $9.1 million in the period. For the year, the company reported that its loss narrowed ...

  • A Look at Regeneron Pharmaceuticals’ Product Pipeline
    Market Realist5 months ago

    A Look at Regeneron Pharmaceuticals’ Product Pipeline

    Regeneron Pharmaceuticals and Its Strong Portfolio of Products

  • Regeneron Pharmaceuticals and Its Financial Performance
    Market Realist5 months ago

    Regeneron Pharmaceuticals and Its Financial Performance

    Regeneron Pharmaceuticals and Its Strong Portfolio of Products